Skip to content
type1.science

Medtronic MiniMed 780G (SmartGuard)

Medtronic

An advanced hybrid closed-loop system whose SmartGuard algorithm delivers automatic correction boluses as often as every 5 minutes and offers an aggressive, adjustable 100 mg/dL (5.6 mmol/L) target. Tubed, paired with Medtronic's own Guardian 4 (or newer Simplera Sync) sensor, with strong trial and real-world time-in-range and the ability to absorb missed or under-estimated meal boluses.

Available nowStrong evidencehybrid-closed-looptubedphone-controlOfficial site ↗

The scorecard

Time in range80

Real-world cohorts average ~76% TIR (Latin America, n=1025) and the US pivotal trial reached 75% overall (78.8% at the 100 mg/dL target); among the strongest of mainstream AID systems.

Hypo protection80

Predictive low-glucose suspension keeps real-world time-below-range low (~2.7% <70 mg/dL; <1% in large cohorts) even while pushing an aggressive target, with no severe-hypo or DKA events in the ADAPT RCT.

Automation level70

Meal-detection auto-corrections fire as often as every 5 minutes to absorb missed or under-estimated boluses, but meals must still be announced, so it remains a hybrid (not fully closed) loop.

Average glucose80

The 100 mg/dL target and frequent auto-corrections drive low mean glucose: real-world GMI ~6.7-6.95% and trial HbA1c falling to ~7.3% from a high-8% baseline.

Low variability72

Good coefficient-of-variation control in real-world data; large unannounced meals and rapidly absorbing carbs still produce excursions the loop cannot fully blunt.

Exercise handling64

A manually set Temp Target of 150 mg/dL (8.3 mmol/L) raises the target to limit activity lows, but there is no automatic exercise detection.

Customizability70

Adjustable SmartGuard target (100/110/120 mg/dL) and active-insulin time let users tune aggressiveness; the optimal-settings combination materially raises TIR.

Access & cost62

FDA-approved (ages 7+) and broadly available across the US, UK, EU, Canada and Australia through durable-medical-equipment channels, though it is a closed, Medtronic-only ecosystem.

Freedom (form factor)46

A tubed pump with a separate body, tubing and an infusion set to carry and disconnect for showering or sport.

Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.

The full picture

The MiniMed 780G is Medtronic's advanced hybrid closed-loop (AHCL) system. It combines a tubed insulin pump, one of Medtronic's own continuous glucose monitors (the Guardian 4 sensor, and in newer markets the disposable Simplera Sync), and the SmartGuard algorithm, which automatically adjusts background insulin and adds correction doses to keep glucose near a target you choose.12

What makes it distinctive is how assertive the algorithm is. You pick a target of 100, 110, or 120 mg/dL (5.6, 6.1, or 6.7 mmol/L); the default and lowest, 100 mg/dL, is the most aggressive of any approved automated pump.31 On top of automated basal, SmartGuard delivers automatic correction boluses as often as every 5 minutes when basal is maxed out and sensor glucose climbs above 120 mg/dL, and its meal-detection feature gives larger corrections when it sees the rapid rise of a missed or under-estimated meal bolus.31

Trial outcomes are strong. In the ADAPT randomized trial, adults with poorly controlled type 1 diabetes (starting HbA1c ~9%) who switched from injections-plus-scanning to the 780G dropped HbA1c by 1.54% to 7.32%, versus almost no change on injections — a 1.42% advantage, with no severe hypoglycemia or ketoacidosis.4 Those gains held at 12 months, and late switchers reproduced them.5 Medtronic's US pivotal trial reported 75% time-in-range overall, 82% overnight, and 78.8% when using the 100 mg/dL target.1 Large real-world datasets agree: across ~1,000 Latin American users, mean GMI was 6.7%, time-in-range 76.5%, and time-below-range just 2.7%, improving with each system generation.6

Automation and meals. This is still a hybrid loop — you announce meals by counting carbs and bolusing. The payoff of the aggressive auto-corrections is that the cost of a forgotten or under-counted meal is smaller than on gentler systems. In a 2025 real-world study of youth and young adults switching to the recommended settings (100 mg/dL target plus 2-hour active-insulin time), time-in-range improved from 71.9% before the switch to 75.0% at 3 months without a significant increase in time below range.7

Exercise is handled with a manually set Temp Target of 150 mg/dL (8.3 mmol/L) that you turn on before activity to reduce lows; there is no automatic activity detection.3

Ages, indications, and access. The FDA approved the 780G in April 2023 for people aged 7 and older with type 1 diabetes, paired with the Guardian 4 sensor (no fingersticks needed in SmartGuard).18 It is widely available in the US, UK, EU, Canada and Australia. Real-world studies show benefit well beyond the label, including young children aged 2-6 (≈73% TIR),9 youth over a full year,10 all ages in real-world clinics,2 and — though not formally approved for it — pregnancy, where a randomized trial found improved overnight time-in-range and less hypoglycemia.11

What's coming. Medtronic has broadened sensor options: the disposable, all-in-one Simplera Sync sensor gained FDA approval for use with the 780G in April 2025, replacing the bulkier Guardian 4 with a smaller two-step insertion and no overtape.12 The closed, single-vendor ecosystem remains the main trade-off against the more open and DIY platforms.

References

  1. Medtronic. FDA Approves Medtronic MiniMed 780G System — World's First Insulin Pump with Meal Detection Technology Featuring 5-Minute Auto Corrections. Medtronic News (2023). https://news.medtronic.com/2023-04-21-FDA-Approves-Medtronic-MiniMed-TM-780G-System-Worlds-First-Insulin-Pump-with-Meal-Detection-Technology-Featuring-5-Minute-Auto-Corrections ↩ ↩2 ↩3 ↩4 ↩5

  2. Elbarbary NS, Ismail EAR. MiniMed 780G advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: real-world users. Diabetol Metab Syndr (2023). https://doi.org/10.1186/s13098-023-01184-w ↩ ↩2

  3. Medtronic / MiniMed. SmartGuard Technology — MiniMed 780G System Support. minimed.com (accessed 2026). https://www.minimed.com/en-us/support/product-support/780g/smartguard-technology/ ↩ ↩2 ↩3

  4. Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol (2022). https://doi.org/10.1016/S2213-8587%2822%2900212-1 ↩

  5. Edd SN, Castañeda J, Choudhary P, et al. Twelve-month results of the ADAPT randomized controlled trial. Diabetes Obes Metab (2023). https://doi.org/10.1111/dom.15217 ↩

  6. Grassi B, Gómez AM, Calliari LE, et al. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America. Diabetes Obes Metab (2023). https://doi.org/10.1111/dom.15023 ↩

  7. Bassi M, Spacco G, Pezzotta F, et al. Real-world efficacy of MiniMed 780G recommended settings (glycemic target 100 mg/dL, active insulin time 2 hours) in youth and young adults with type 1 diabetes. Front Endocrinol (2025). PMID 41019322. https://doi.org/10.3389/fendo.2025.1670266 ↩

  8. U.S. FDA. PMA Supplement P160017/S091 — Medtronic MiniMed 780G System approval order/summary. accessdata.fda.gov (2023). https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160017S091A.pdf ↩

  9. Abraham MB, Smith GJ, Dart J, et al. Clinical Outcomes with MiniMed 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes. Diabetes Technol Ther (2024). https://doi.org/10.1089/dia.2023.0508 ↩

  10. Passanisi S, Salzano G, Bombaci B, et al. Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in Children and Adolescents: A 1-Year Real-World Study. Diabetes Care (2024). https://doi.org/10.2337/dc23-2311 ↩

  11. Benhalima K, Beunen K, Van Wilder N, et al. Advanced hybrid closed loop therapy versus standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a randomised controlled trial. Lancet Diabetes Endocrinol (2024). https://doi.org/10.1016/S2213-8587%2824%2900089-5 ↩

  12. Medtronic. New Simplera Sync sensor for the MiniMed 780G System now FDA approved. Journal of Healthcare Contracting (2025). https://www.jhconline.com/new-simplera-sync-sensor-for-the-minimed-780g-system-now-fda-approved.html ↩

What's next for this

  • →Disposable all-in-one Simplera Sync sensor gained FDA approval for use with the 780G, replacing the bulkier Guardian 4 · April 2025